Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1588-1593

  Payne, Richard ^a   Mathias, Susan D ^a   Pasta, David J ^a   Wanke, Lee A ^a   Williams, Rhys ^a   Mahmoud, Ramy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; MORPHINE; MORPHINE SULFATE; OXYCODONE;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATIENT ATTITUDE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; SLEEP TIME; TRANSDERMAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031925637     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1588     Document Type: Article

References (18)

1. Jacox A, Carr DB, Payne R, et al: Management of Cancer Pain. Clinical Practice Guideline No. 9. Agency for Health Care Policy and Research publication no. 94-0592. Rockville, MD, United States Department of Health and Human Services, Public Health Service, March 1994
2. Payne R, Moran K, Southam M: The role of transdermal fentanyl in the management of cancer pain, in Estafanous FG (ed): Opioids in Anesthesia II. Stoneham, MA, Butterworth, 1990, pp 215-222
3. Payne R, Chandler S, Einhaus M: Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs 6:50-53, 1995
4. Ferrell BR, Dow KH, Grant M: Measurement of the quality of life in cancer survivors. Qual Life Res 4:523-531, 1995
5. Ferrell BR: The impact of pain on quality of life. A decade of research. Nurs Clin North Am 30:609-624, 1995
6. TTS-Fentanyl Multicentre Study Group: Transdermal fentanyl in cancer pain. J Drug Dev 6:93-97, 1994
7. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
8. Donnelly S, Walsh D: Quality of life assessment in advanced cancer. Palliat Med 10:275-283, 1996
9. Portenoy RK, Thaler HT, Kornblith AB, et al: The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A: 1326-1336, 1994
10. Cleeland CS: Assessment of pain in cancer: Measurement issues, in Foley KM, Bonica JJ, Ventafridda V, et al (eds): Advances in Pain Research and Therapy (vol 16). New York, NY, Raven, 1990, p 52
11. Gear RW, Miashowski C, Gordon NC, et al: Kappa-opiods produce significantly greater analgesia in women than in men. Nat Med 2:1248-1250, 1995
12. Fillingim RB, Maixner W: Gender differences in the responses to noxious stimuli. Pain For 4:209-221, 1995
13. Reisine T, Pasternak G: Opioid analgesics and antagonists, in Hardman JG, Limbird LE (eds): Goodman and Gilman's the Pharmacologic Basis of Therapeutics (ed 9). New York, NY, McGraw Hill, 1996, pp 523-527
14. Aaronson NK: Quality of life: What is it? How should it be measured? Oncology 2:69-76, 1988
15. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained release oral morphine in cancer pain: Preference, efficacy and quality of life. J Pain Symptom Manage 13:254-261, 1997
16. American Pain Society Quality of Care Committee: Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA 274:1874-1880, 1995
17. Serlin RC, Mendoza TR, Nakamura Y, et al: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-284, 1995
18. Hammack JE, Loprinzi CL: Use of orally administered opioids for cancer-related pain. Mayo Clin Proc 69:384-390, 1994